Cibus Inc. (CBUS)
NASDAQ (CM) NASDAQ (CM) Primary 
Cibus (CBUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cibus (CBUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cibus, Inc. (CBUS) Q4 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Carlo Broos - Interim Chief Financial Officer Peter Beetham - Co-Founder, President and COO, Interim CEO Greg Gocal - Co-Founder and Chief Scientific Officer and Executive Vice President Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Sameer Joshi - H. C. Wainwright Matthew Venezia - Alliance Global Partners Operator Good afternoon, and welcome to the Cibus Fourth Quarter 2024 Results Conference Call.
Cibus, Inc. (CBUS) Q3 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Matthew Venezia - Alliance Global Partners Operator Good day, and welcome to the Cibus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Cibus (CBUS) Q3 Earnings and Revenues Top Estimates
Cibus (CBUS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.90 per share. This compares to loss of $1.59 per share a year ago.
Cibus, Inc. (CBUS) Q2 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Nick Anderson - ROTH Capital Matthew Venezia - Alliance Global Partners Austin Moeller - Canaccord Sameer Joshi - H.C. Wainwright Steve Byrne - Bank of America Operator I'd like to turn the conference over to Wade King, Chief Financial Officer.
Cibus (CBUS) Reports Q2 Loss, Tops Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $3.05 per share a year ago.
Levi & Korsinsky Reminds Cibus, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CBUS
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ:CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Announces an Investigation on Behalf of Cibus, Inc. (CBUS) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.
An Investigation Has Commenced on Behalf of Cibus, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CBUS Losses.
NEW YORK, NY / ACCESSWIRE / July 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cibus, Inc. (CBUS) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.
Levi & Korsinsky Reminds Cibus, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CBUS
NEW YORK, NY / ACCESSWIRE / July 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.
